Background: Elevated levels of plasma D-dimer increase the risk of ischemic stroke, stroke severity, and the progression of stroke status, but the association between plasma D-dimer level and functional outcome is unclear. The aim of this study is to investigate whether plasma D-dimer level is a determinant of short-term poor functional outcome in patients with acute ischemic stroke (AIS). Methods: This prospective study included 877 Chinese patients with AIS admitted to Renmin Hospital of Wuhan University within 72 h of symptom onset. Patients were categorized by plasma D-dimer level: Quartile 1(≤0.24 mg/L), Quartile 2 (0.25–0.56 mg/L), Quartile 3 (0.57–1.78 mg/L), and Quartile 4 (>1.78 mg/L). The medical record of each patient was reviewed, and demographic, clinical, laboratory and neuroimaging information was abstracted. Functional outcome at 90 days was assessed with the modified Rankin Scale. Results: Poor outcome was present in 302 (34.4%) of the 877 patients that were included in the study (mean age, 64 years; male, 68.5%). After adjustment for potential confounding variables, higher plasma D-dimer level on admission was associated with poor outcome (adjusted odds ratio 2.257, 95% confidence interval 1.349–3.777 for Q4:Q1; P trend = 0.004). According to receiver operating characteristic (ROC) analysis, the best discriminating factor for poor outcome was a plasma D-dimer level ≥0.315 mg/L (area under the ROC curve 0.657; sensitivity 83.8%; specificity 41.4%). Conclusion: Elevated plasma D-dimer levels on admission are significantly associated with poor outcome after admission for AIS, suggesting the potential role of plasma D-dimer level as a predictive marker for short-term poor outcome in patients with AIS.
Research article
Elevated plasma D-dimer levels are associated with short-term poor outcome in patients with acute ischemic stroke: a prospective, observational study
https://doi.org/10.21203/rs.2.9184/v4
This work is licensed under a CC BY 4.0 License
Journal Publication
published 22 Jul, 2019
You are reading this latest preprint version
Epidemiological investigations have concluded that stroke is a leading cause of adult disability and mortality, and poses a serious public health burden worldwide [1-3]. Recently, the multicenter Global Burden of Disease (GBD 2016) Study found that the risk of ischemic stroke was 18.3% and the risk of hemorrhagic stroke was 8.2% among adults 25 years of age or older [4]. As a predominant stroke subtype in Chinese populations [5], acute ischemic stroke (AIS) reached 66.4% among the stroke subtypes between September 2007 and August 2008 in the Chinese National Stroke Registry [6]. Because of the high morbidity and risk of disability after AIS, an estimation of prognosis is an emergent issue, especially when physicians are confronted with concerns from patients and families. Recent studies have assessed prognostic factors such as glycemic index, body mass index (BMI), and uric acid, but their prognostic values in relation to AIS was inconsistent [7-12]. For specific management of stroke rehabilitation in regard to the neurological functional outcome, identifying more powerful predictors of clinical prognosis is warranted.
D-dimer is a soluble fibrin degradation final product and derived from the cross-linked fibrin network as it undergoes plasmin-mediated degradation. The plasma D-dimer level increases during blood thrombosis and degradation of fibrin, therefore plasma D-dimer could be a biological marker of hemostatic abnormalities and thrombosis [ 1]. Elevated plasma D-dimer levels are reportedly a determinant of stroke progression [ 2], infarction volume [ 3], and the incidence of stroke [ 4]. Recently, many studies have investigated whether plasma D-dimer levels are a determinant of poor functional outcomes after AIS, however, the conclusions of the studies were controversial [ 5-8]. Some investigators have found that plasma D-dimer levels could independently predict poor functional outcomes in patients with AIS [ 5, 6], while other investigators have reported conflicting results [ 7, 8].
Accordingly, the aim of this study was to investigate whether elevated plasma D-dimer levels could be a significant determinant of poor outcome after admission for AIS.
Study population
This was a prospective follow-up study. Data were retrospectively analyzed from a prospective registry. We enrolled 877 consecutive Chinese patients with AIS at Renmin Hospital of Wuhan University from January 2017 to August 2018. All patients were admitted within 72 h of experiencing a new focal or global neurological event. AIS was diagnosed according to the World Health Organization criteria [
9
</a>] combined with brain computed tomography or magnetic resonance confirmation within
72 h. Patients were excluded if any of the following criteria were met: a delay of
72 h from symptom recognition to admission, age younger than 18 years, preexisting significant
disability (defined as modified Rankin scale, mRS 2) from any condition, intracranial
hemorrhage, malignancy, febrile disorders, and acute or chronic inflammatory disease
at study enrollment. Each participant was followed up after 3 months via telephone,
email, and face to face. The study protocol complied with the Declaration of Helsinki and was approved by the
Wuhan University Ethics Committee.</p>
Demographic and clinical assessment
Socio-demographic, self-reported medical history, and vascular risk biomarker data were assessed and included: age, sex, BMI, history of hypertension, diabetes, alcohol consumption, smoking, dyslipidemia, atrial fibrillation, previous stroke, and coronary artery disease (CAD). The National Institutes of Health Stroke Scale (NIHSS) scores were used by stroke neurologists to assess neurological deficit when the patients were admitted [ 10]. Stroke subtype was classified according to the Trial of Org 10172 in acute stroke treatment (TOAST classification) criteria [ 11], which distinguished large-artery arteriosclerosis, small-artery occlusion, cardioembolism, other causative factor, and undetermined causative factor.
Fasting plasma glucose (FPG) and plasma D-dimer level were measured in the morning after at least 8 h of fasting. Plasma D-dimer level was measured for all patients with a particle-enhanced immunoturbidimetric assay in a calibrated SYSMEX7000 analyzer (Sysmex Corporation, Hyogo, Japan). The normal range of morning plasma D-dimer concentration in our hospital laboratory is 0–0.55 mg/L.
Follow-up and short-term outcomes
Patient follow-up was performed at 90 days after stroke onset. The prognosis outcome was assessed with modified Rankin Scale (mRS) via telephone, email, and face to face by a trained research nurse or neurologist. A good functional outcome was defined as an mRS of 0–2 points, whereas a poor outcome was defined as an mRS of 3–6 points.
Statistical analysis
For continuous variables, data are expressed either as the means ± standard deviations (SD) or medians (interquartile ranges, IQR). Categorical variables are expressed as frequencies and percentages. The patients were categorized into two groups according to prognosis outcome (good outcome vs poor outcome). A two-group comparison of normally distributed continuous variables was assessed using independent t-tests. The non-parametric Mann–Whitney U test was used for continuous variables that were not normally distributed. The χ2 test was used for categorical variables. Furthermore, we categorized the patients into four quartile groups according to their plasma D-dimer level at admission. A four-group comparison was assessed using the χ2 test, one-way analysis of variance (ANOVA) and Mann–Whitney U tests, as appropriate. Multivariate analysis adjustment for variables was performed for the correlation between the quartiles of plasma D-dimer levels and poor outcome by logistic regression analysis, which used methods from previous studies [ 12, 13]. Results were expressed as adjusted odds ratios (OR) with the corresponding 95% confidence intervals (CIs). Receiver operating characteristic (ROC) curves were utilized to evaluate the accuracy of plasma D-dimer level to predict AIS poor neurological outcome. The area under the curve (AUC) was calculated as a measurement of the accuracy of the test. All statistical analysis was performed with SPSS for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
Baseline characteristics of the patients
A total of 877 AIS patients (median age 64 years, 68.5% male) who met the inclusion criteria were recruited for this study. The variables associated with functional outcome of AIS included sex, age, BMI, vascular risk factors (smoking, alcohol drinking, atrial fibrillation, diabetes, hypertension, CAD, dyslipidemia, previous stroke), baseline systolic blood pressure (SBP), baseline systolic-diastolic blood pressure (DBP), FBG , baseline NIHSS scores and stroke subtype. The median plasma D-dimer level on admission was 0.56 (0.24–1.79) mg /L, and the median NIHSS score on admission was 5 (3–8). In this study, 575 patients (65.6%) presented with good outcomes, 302 patients (34.4%) presented with poor outcomes, and 77 patients (8.8%) died among the 877 patients within 90 days. The baseline characteristics and outcome of the patients with AIS are described in Table 1. The sex, age, BMI, smoker, history of atrial fibrillation, FBG, plasma D-dimer level, baseline NIHSS scores, and stroke etiology were markedly associated with the outcomes of AIS at 90 days (P < 0.05 for all).
Figure 1 shows the plasma D-dimer level between two functional outcome groups. In the patients with poor outcome, plasma D-dimer levels were significantly higher compared with those in patients with good outcomes [0.88 (IQR, 0.42–2.72) mg/L vs 0.46 (IQR, 0.21–1.32) mg/L; Z = −7.655, P = 0.000].
Correlation between plasma D-dimer level and 90-Day functional outcome
Patients were stratified into four groups according to plasma D-dimer quartiles: Plasma D-dimer levels 0.24 (n = 226), 0.25–0.56 (n = 213), 0.57–1.78 (n = 219), and 1.78 mg /L (n = 219) (Table 2). Among the four groups, there were no significant differences in the history of hypertension, diabetes, dyslipidemia, previous stroke, drinking alcohol, FBG, and baseline SBP (P 0.05 for all). Age, sex, BMI, smoking, atrial fibrillation, baseline DBP, baseline NIHSS scores, stroke etiology, and mortality differed among the four groups (P < 0.05 for all). The unadjusted comparisons of the four groups revealed more poor outcomes among the higher quartiles of Plasma D-dimer levels (χ2 = 53.724, P = 0.000) (Figure 2).
Functional outcome stratified for plasma D-dimer levels is shown in Figure 3. Univariate analysis shows a clear relationship between admission plasma D-dimer levels and mRS using the χ2 Test (χ2 = 877.000, P trend = 0.000). Furthermore, the correlation between plasma D-dimer levels and poor outcome after adjustment for variables are detailed in Table 3. In patients with high plasma D-dimer levels, the risk of poor functional outcome at 90 days was significantly increased when compared with the group with low plasma D-dimer levels (P trend = 0.000, OR = 3.800, 95% CI = 2.420–5.965 for Q4: Q1; adjusted for age, sex, and BMI). Additional adjustment for smokers, alcohol drinkers, atrial fibrillation, diabetes, hypertension, CAD, dyslipidemia, previous stroke, baseline SBP, baseline DBP, FBG, baseline NIHSS scores, and stroke etiology did not influence this finding. An overall OR of 2.257 (P trend = 0.004, 95% CI = 1.349–3.777 for Q4: Q1) was found for patients with high plasma D-dimer levels.
Predictive values of plasma D-dimer lev el in patient outcome
To further evaluate the predictive values of plasma D-dimer levels in patients with AIS, the ROC curves and AUCs were created and are depicted in Figure 4. Based on the ROC curve, the optimal cut-off value of plasma D-dimer levels as an indicator for diagnosis of unfavorable functional outcome was projected to be 0.315 mg/L, which yielded a sensitivity of 83.8% and a specificity of 41.4%, the AUC was 0.657 (95% CI, 0.620–0.694; P = 0.000).
In the present study, higher plasma D-dimer level on admission was a significant independent determinant of short-term neurological dysfunction in patients with AIS within 90 days in a Chinese population. After adjusting for various confounders, the correlation remained significant.
Previous prospective epidemiological investigations have concluded that there is a positive association between plasma D-dimer levels and stroke [
14-16
</a>]. In some studies, the results showing that plasma D-dimer levels were associated with stroke severity [<a href="#_ENREF_17">
17
</a>, <a href="#_ENREF_18">
18
</a>], infarct volume [<a href="#_ENREF_3">
3
</a>, <a href="#_ENREF_19">
19
</a>, <a href="#_ENREF_20">
20
</a>], and progression of stroke status [<a href="#_ENREF_2">
2
</a>, <a href="#_ENREF_21">
21
</a>, <a href="#_ENREF_22">
22
</a>]. However, the relationship between plasma D-dimer levels and functional outcome
in patients with AIS has been poorly studied.</p>
The available studies on stroke have shown relationships between plasma D-dimer level and functional outcome in several different population types with AIS [
23-27
</a>]. Nam et al. [<a href="#_ENREF_23">
23
</a>] and Nezu et al. [<a href="#_ENREF_24">
24
</a>] found a predictive role of plasma D-dimer levels only in patients with cryptogenic
stroke. A Canadian study by Kim et al. [<a href="#_ENREF_25">
25
</a>] reported the prognostic value of plasma D-dimer level in patients with noncardioembolic stroke. In a study of a Chinese population
with complicating coronary heart disease, the result indicated that higher plasma
D-dimer levels had a worse outcome within 90 days after the initial onset of AIS [<a href="#_ENREF_26">
26
</a>]. A Swiss study by Hsu et al. reported that a high plasma D-dimer levels indicates
an unfavorable outcome in patients with AIS receiving intravenous thrombolysis [<a href="#_ENREF_27">
27
</a>]. However, on reviewing previous literature, we also found that some other studies
have reported conflicting results. A report by Squizzato et al. [<a href="#_ENREF_7">
7
</a>] revealed that plasma D-dimer level in patients with AIS probably does not predict the functional outcome after adjustment for age
and stroke subtype. Furthermore, two other studies did not even find a meaningful association between plasma D-dimer levels and the prognosis of patients
with AIS [<a href="#_ENREF_28">
28
</a>, <a href="#_ENREF_29">
29
</a>]. </p>
In this study, because the prognostic value did not alter even after adjusting for various confounders such as age, sex, BMI, vascular risk factors, baseline NIHSS scores, and stroke etiology, our results revealed plasma D-dimer levels are an independent biological prognostic marker of AIS. In fact, the positive value of plasma D-dimer in patients with all subtypes of AIS was indicated in several previous studies [33, 41, 42], which is consistent with our findings.
D-dimer derived from the cross-linked fibrin network is a final soluble fibrin degradation product which undergoes plasmin-mediated degradation [
1
</a>]. Plasma D-dimer could be elevated in a population with thrombotic diseases such as pulmonary
embolism and venous thromboembolism [<a href="#_ENREF_30">
30
</a>, <a href="#_ENREF_31">
31
</a>], however, the mechanism remains unclear. There are several possible explanations for
why plasma D-dimer levels might be relevant to poor functional outcome in patients
with AIS. For instance, plasma D-dimer level increases in blood coagulation and degradation
of fibrin and could be a marker of thrombosis based on the underlying mechanisms [<a href="#_ENREF_32">
32
</a>, <a href="#_ENREF_33">
33
</a>]. Moreover, a high plasma D-dimer levels may result in resistance to the endogenous
fibrinolytic system and influence thromboembolism formation [<a href="#_ENREF_28">
28
</a>, <a href="#_ENREF_34">
34
</a>]. Furthermore, plasma D-dimer also stimulates the immune system and leads to changes
in inflammatory mediators levels such as IL-1, TNF-alpha, IL-6, and IL-8 [<a href="#_ENREF_35">
35
</a>, <a href="#_ENREF_36">
36
</a>]. Activated inflammation may contribute to the pathological alteration in patients
with AIS [<a href="#_ENREF_37">
37
</a>]. In addition, infarct volume, initial stroke severity, and progression of stroke
status were correlated with a high plasma D-dimer levels [<a href="#_ENREF_2">
2
</a>, <a href="#_ENREF_17">
17-22
</a>], therefore elevated plasma D-dimer levels may predict poor outcome through the aggravation
of cerebral tissue damage by disturbing recanalization and increasing reperfusion
injury. Additionally, the plasma D-dimer levels in patients with AIS may identify those who
may benefit from additional interventions, targeting some of the mechanisms mentioned
above. This needs to be explored in further studies.</p>
The present study has several limitations. First, this is a single-center, observational study. The sample sizes of patients are small, and selection bias was a major concern, thereby limiting the power to generalize our results. Second, the plasma D-dimer levels were measured only in the morning after at least 8 h of fasting in our study, however, recording the serial change of plasma D-dimer levels might better explore the correlation between D-dimer and outcome after AIS. Finally, our study explored the short-term outcome with an end-point defined at 90 days. The correlation between plasma D-dimer levels and long-term prognosis requires further confirmation in our study population. Therefore, further multicenter studies with a larger sample size need to be conducted.
Elevated plasma D-dimer levels on admission are significantly associated with poor outcome after admission for AIS, suggesting a high plasma D-dimer level within 72 h of a stroke as a predictive marker for short-term poor outcome after 90 days in patients with AIS. Plasma D-dimer level is a convenient and economical biological indicator that could be used for improving the specific management of stroke rehabilitation and functional outcome.
AIS: acute ischemic stroke; mRS: modified Rankin Scale; BMI: body mass index ; CAD: coronary artery disease; NIHSS: National Institutes of Health Stroke Scale; TOAST: Trial of Org 10,172 in Acute Stroke Treatment; FPG: fasting plasma glucose; SD: standard deviations; IQR: interquartile ranges; ANOVA: analysis of variance; OR: odds ratio; CI: confidence interval; ROC: receiver operating characteristic; AUC: area under the ROC curve; SBP: systolic blood pressure; DBP: diastolic blood pressure; IL: interleukin; TNF: tumor necrosis factor
Ethics approval and consent to participate
This study is approved by the Ethics Committee of Wuhan Universit. All participants gave written informed consent for participation and publication.
Consent for publication
Not applicable.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Competing interests
The authors declare that they have no competing interests.
Funding
This study was supported by the National Natural Science Foundation of China (No. 81401051) and the Hubei Provincial Natural Science Foundation of China (No. 2016CFB575).The funding bodies did not influence the study design, the collection, analysis, and interpretation of data, the manuscript writing, and the decision to submit it for publication.
Authors’ contributions
TY interpreted the patient data and were the main contributors in writing the manuscript. TY, BLT, GL, DH, and YQZ performed the statistical analysis and were a major contributor in writing the manuscript. QC, CFW, QZ, BP, YG, and LX collected the data and were the major contributors in writing the manuscript. GHW participated in study design, data interpretation and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Acknowledgments
We thank all the participants for their participation in this study.
Author details
1Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, China
2Department of Neurology, Dawu County Hospital of Traditional Chinese Medicine, Hubei 432800, China
3Emergency Department, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China
4Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China
5Institute of Neuropsychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China
1. Weitz JI, Fredenburgh JC, Eikelboom JW: A Test in Context: D-Dimer. Journal of the American College of Cardiology 2017, 70(19):2411.
2. Mark B, Peter L, Ann R, Lowe GDO, Stott DJ: Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke 2004, 35(6):1421-1425.
3. Mari M, Manabu S, Shuhei O, Shigetaka F, Masafumi T, Hideki E, Takeshi S, Toshiki Y, Hideki M, Kazuo K: Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation. Cerebrovascular Diseases 2013, 35(1):64-72.
4. Zhang J, Song Y, Shan B, He M, Ren Q, Zeng Y, Liu Z, Liu H, Xu J: Elevated level of D-dimer increases the risk of stroke. Oncotarget 2018, 9(2):2208-2219.
5. Paul W, Mark B, Peter L, Ann R, Lowe GDO, Stott DJ: Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovascular Diseases 2009, 27(3):247-253.
6. Dougu N, Takashima S, Sasahara E, Taguchi Y, Toyoda S, Hirai T, Nozawa T, Tanaka K, Inoue H: Predictors of poor outcome in patients with acute cerebral infarction. Journal of Clinical Neurology 2011, 7(4):197-202.
7. Squizzato A, Ageno W, Finazzi S, Mera V, Romualdi E, Bossi A, Venco A: D-dimer is not a long-term prognostic marker following acute cerebral ischemia. Blood Coagulation & Fibrinolysis 2006, 17(4):303-306.
8. Haapaniemi E, ., Tatlisumak T, . Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurologica Scandinavica 2010, 119(3):141-150.
9. Listed N: Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke; a journal of cerebral circulation 1989, 20(10):1407.
10. Brott T, ., Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, ., Spilker J, ., Holleran R, ., Eberle R, ., Hertzberg V, . Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989, 20(7):864-870.
11. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1):35-41.
12. Deng QW, Wang H, Sun CZ, Xing FL, Zhang HQ, Zuo L, Gu ZT, Yan FL: Triglyceride to high-density lipoprotein cholesterol ratio predicts worse outcomes after acute ischaemic stroke. Eur J Neurol 2017, 24(2):283-291.
13. Luitse MJ, Velthuis BK, Kappelle LJ, van der Graaf Y, Biessels GJ: Chronic hyperglycemia is related to poor functional outcome after acute ischemic stroke. International journal of stroke : official journal of the International Stroke Society 2017, 12(2):180-186.
14. Di Castelnuovo A, Agnoli C, de Curtis A, Giurdanella MC, Sieri S, Mattiello A, Matullo G, Panico S, Sacerdote C, Tumino R et al: Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study. Thrombosis and haemostasis 2014, 112(5):941-946.
15. Folsom AR, Gottesman RF, Appiah D, Shahar E, Mosley TH: Plasma d-Dimer and Incident Ischemic Stroke and Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Stroke 2016, 47(1):18.
16. Hamatani Y, Nagai T, Nakai M, Nishimura K, Honda Y, Nakano H, Honda S, Iwakami N, Sugano Y, Asaumi Y et al: Elevated Plasma D-Dimer Level Is Associated With Short-Term Risk of Ischemic Stroke in Patients With Acute Heart Failure. Stroke 2018, 49(7):1737-1740.
17. Berge E, Friis P, Sandset PM: Hemostatic Activation in Acute Ischemic Stroke ☆. Thrombosis Research 2001, 101(2):13-21.
18. Barbieri A, ., Giuliani E, ., Carone C, ., Pederzoli F, ., Mascheroni G, ., Greco G, ., Stucchi C, ., Genedani S, . Clinical severity of ischemic stroke and neural damage biomarkers in the acute setting: the STROke MArkers (STROMA) study. Minerva Anestesiologica 2013, 79(7):750.
19. Young-Woo P, Eun-Jeong K, Ha-Young C: Correlation between Serum D-Dimer Level and Volume in Acute Ischemic Stroke. Journal of Korean Neurosurgical Society 2011, 50(2):89.
20. Zi WJ, Shuai J: Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. Plos One 2014, 9(1):e86465.
21. Mark B, Peter L, Ann R, Lowe GDO, Stott DJ: D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke; a journal of cerebral circulation 2006, 37(4):1113-1115.
22. Zang R, Zhang H, Xu Y, Zhang S, Liu X, Wang J, Gao Y, Shu M, Mei B, Li H: Serum C-reactive protein, fibrinogen and D-dimer in patients with progressive cerebral infarction. Translational Neuroscience 2016, 7(1):84-88.
23. Nam KW, Kim CK, Kim TJ, An SJ, Demchuk AM, Kim Y, Jung S, Han MK, Ko SB, Yoon BW: D-dimer as a predictor of early neurologic deterioration in cryptogenic stroke with active cancer. European Journal of Neurology 2016, 24(1).
24. Nezu T, Kitano T, Kubo S, Uemura J, Yamashita S, Iwanaga T, Inoue T, Hosomi N, Maruyama H, Matsumoto M: Impact of D-dimer levels for short-term or long-term outcomes in cryptogenic stroke patients. Journal of Neurology 2018, 265(3):1-9.
25. Kim TW, Song IU, Chung SW: Prognostic Value of Serum D-Dimer in Noncardioembolic Ischemic Stroke. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2017, 44(4):404-409.
26. Wang Y, Hafeez A, Meng F, Zhang R, Wang X, Chen X, Kong Q, Du H, Ma X: The correlation of D-dimer levels with patient outcomes in acute ischemic cerebrovascular disease complicating coronary heart disease. Neurological Research 2016, 38(6):524-532.
27. Hsu PJ, Chen CH, Yeh SJ, Tsai LK, Tang SC, Jeng JS: High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis. Cerebrovasc Dis 2016, 42(1-2):117-121.
28. Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG: Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagulation & Fibrinolysis 2002, 13(4):339-347.
29. Rallidis LS, Vikelis M, ., Panagiotakos DB, Liakos GK, Krania E, ., Kremastinos DT: Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurologica Scandinavica 2010, 117(6):415-420.
30. Keller K, Beule J, Balzer JO, Dippold W: D-Dimer and thrombus burden in acute pulmonary embolism. The American journal of emergency medicine 2018, 36(9):1613-1618.
31. Sartori M, Migliaccio L, Favaretto E, Cini M, Legnani C, Palareti G, Cosmi B: D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis. Thromb Res 2015, 135(4):673-678.
32. Matsuo T, ., Kobayashi H, ., Kario K, ., Suzuki S, . Fibrin D-dimer in thrombogenic disorders. Seminars in Thrombosis & Hemostasis 2000, 26(01):101-107.
33. Kogan AE, Mukharyamova KS, Bereznikova AV, Filatov VL, Koshkina EV, Bloshchitsyna MN, Katrukha AG: Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products. Blood Coagulation & Fibrinolysis 2016, 27(5):542-550.
34. Urbach H, ., Hartmann A, ., Pohl C, ., Omran H, ., Wilhelm K, ., Flacke S, ., Schild HH, Klockgether T, . Local intra-arterial thrombolysis in the carotid territory: does recanalization depend on the thromboembolus type? Neuroradiology 2002, 44(8):695.
35. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS: D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002, 121(4):1262.
36. Robson SC, Shephard EG, Kirsch RE: Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 2010, 86(2):322-326.
37. Mar C, José C, García MM, Rogelio L, Joaquín S, Angel C, Antoni D: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002, 33(4):982-987.
Table 1 Baseline characteristics of the study patients grouped by 90-day functional outcome
Variable | all (n=877) | good outcome (n=575) | poor outcome (n=302) | P value | |
Age (years) , median (IQR) | 64.00 (54.50-73.00) | 62(52-70) | 68(60-77.25) | 0.000 | |
Sex (male) , n (%) | 601(68.5) | 413(71.8) | 188(62.3) | 0.004 | |
BMI (kg/m2) ,(Mean± SD) | 25.09±3.64 | 24.76±3.54 | 25.70±3.74 | 0.000 | |
Smoker , n (%) | 337(38.4) | 217(37.7) | 120(39.7) | 0.307 | |
Alcohol drinkers , n (%) | 192(21.9) | 137(23.8) | 55(18.2) | 0.056 | |
Hypertension , n (%) | 531(60.5) | 336(58.4) | 195(64.6) | 0.077 | |
Diabetes mellitus , n (%) | 281(32.0) | 172(29.9) | 109(36.1) | 0.062 | |
CAD , n (%) | 106(12.1) | 61(10.6) | 45(14.9) | 0.064 | |
Atrial fibrillation , n (%) | 110(12.5) | 44(7.7) | 66(21.9) | 0.000 | |
Dyslipidemia , n (%) | 309(35.2) | 209(36.3) | 100(33.1) | 0.341 | |
Previous stroke , n (%) | 116(13.2) | 73(12.7) | 43(14.2) | 0.522 | |
NIHSS on admission , median (IQR) | 5(3-8) | 5(3-7) | 7(5-8) | 0.000 | |
SBP(mmHg) , median (IQR) | 147(131-164) | 147(132-162) | 147(130-165) | 0.949 | |
DBP (mmHg) , median (IQR) | 83(75-92) | 83(75-92) | 83(74-92) | 0.229 | |
FBG (mmol/L) , median (IQR) | 6(4.81-8.22) | 5.62(4.63-7.50) | 6.70(5.46-9.50) | 0.000 | |
D-dimer (mg /L) , median (IQR) | 0.56(0.24-1.79) | 0.46(0.21-1.32) | 0.88(0.42_2.72) | 0.000 | |
Stroke etiology , n (%) |
|
|
| 0.000 | |
Large-vessel occlusive | 344(39.2) | 176(30.6) | 168(55.6) |
|
|
Small-vessel occlusive | 366(41.7) | 312(54.3) | 54(17.9) |
|
|
Cardioembolic | 88(10) | 32(5.6) | 56(18.5) |
|
|
Other | 30(3.4) | 21(3.7) | 9(3.0) |
|
|
Undetermined | 49(5.6) | 34(5.9) | 15(5.0) |
|
|
BMI: body mass index; CAD: coronary artery disease; NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; DBP: diastolic blood pressure; IQR: interquartile range; SD: standard deviation.
a χ2 test, independent t-tests, or Mann–Whitney U test, as appropriate.
Table 2 Baseline characteristics of the study patients grouped by plasma D-dimer quartile
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
|
| (≤ 0.24) n=226 | (0.25-0.56) n=213 | (0.57-1.78) n=219 | (＞1.78) n=219 | Pvaluea |
Age (years), median (IQR) | 59(50-66) | 66(58-74) | 66(53-76) | 66(57-76) | 0.000 |
Sex (male) , n (%) | 172(76.1) | 152(71.4) | 142(64.8) | 135(61.6) | 0.005 |
BMI(kg/m2) ,(Mean± SD) | 24.89±3.52 | 24.79±3.56 | 24.99±3.64 | 25.69±3.78 | 0.040 |
Smoker , n (%) | 102(45.1) | 90(42.3) | 74(33.8) | 71(32.4) | 0.012 |
Alcohol drinker , n (%) | 56(24.8) | 51(23.9) | 44(20.1) | 41(18.7) | 0.344 |
Hypertension , n (%) | 138(61.1) | 131(63.5) | 130(59.4) | 133(60.7) | 0.972 |
Diabetes mellitus , n (%) | 83(36.7) | 71(33.3) | 55(25.1) | 72(32.9) | 0.062 |
CAD, n (%) | 18(8.0) | 24(11.3) | 27(12.3) | 37(16.9) | 0.036 |
Atrial fibrillation , n (%) | 10(4.4) | 23(10.8) | 30(13.7) | 47(21.5) | 0.000 |
Dyslipidemia , n (%) | 90(39.8) | 80(37.6) | 63(28.8) | 76(34.7) | 0.085 |
Previous stroke , n (%) | 22(9.7) | 38(17.8) | 28(12.8) | 28(12.8) | 0.093 |
NIHSS on admission, median (IQR) | 4(3-7) | 5(3-7) | 6(3-7) | 7(5-10) | 0.000 |
SBP (mmHg), median (IQR) | 148(134-165) | 145(131-162) | 144(130-162) | 152(134-166) | 0.221 |
DBP (mmHg), median (IQR) | 85(78-95) | 82(76-90) | 80(74-90) | 84(76-93) | 0.001 |
FBG (mmol/L), median (IQR) | 5.7(4.66-8.23) | 6.01(4.95-7.85) | 5.90(4.78-7.46) | 6.23(5.00-9.10) | 0.089 |
D-dimer (mg /L), median (IQR) | 0.17（0.12-0.21） | 0.38（0.31-0.48） | 0.92（0.72-1.27） | 3.06（2.45-3.97） | 0.000 |
Stroke etiology, n (%) |
|
|
|
| 0.000 |
Large-vessel occlusive | 81(35.8) | 82(38.5) | 86(39.3) | 95(43.4) |
|
Small-vessel occlusive | 118(52.2) | 93(43.7) | 91(41.6) | 64(29.2) |
|
Cardioembolic | 7(3.1) | 18(8.5) | 24(11) | 39(19.8) |
|
Other | 12(5.3) | 7(3.3) | 5(2.3) | 6(2.7) |
|
Unknown | 8(3.5) | 13(6.1) | 13(5.9) | 15(6.8) |
|
Mortality, n (%) | 4(1.8) | 13(6.1) | 24(11) | 36(16.4) | 0.000 |
BMI: body mass index; CAD: coronary artery disease; NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; DBP: diastolic blood pressure; IQR: interquartile range; SD: standard deviation.
a χ2 test, ANOVA or Mann–Whitney U tests, as appropriate.
Table 3 Adjusted odds ratios for poor outcome according to plasma D-dimer levels
Quartile 1 | Quartile 2 | P value | Quartile 3 | P value | Quartile 4 | P value | P for trend | |
OR (95% CI)a | 1 | 2.139（1.348-3.393） | 0.001 | 2.518（1.596-3.974） | 0.000 | 3.800（2.420-5.965） | 0.000 | 0.000 |
OR (95% CI)b | 1 | 2.021（1.225-3.334） | 0.006 | 2.503（1.527-4.105） | 0.000 | 3.181（1.964-5.201） | 0.000 | 0.000 |
OR (95% CI)c | 1 | 2.028（1.208-3.405） | 0.007 | 2.246（1.345-3.749） | 0.002 | 2.257（1.349-3.777） | 0.002 | 0.004 |
OR: odds ratio; CI: confidence interval; ORa, adjusted for age, sex, and body mass index. ORb, as note a with additional adjustment for smokers, alcohol drinkers, atrial fibrillation, diabetes, hypertension, CAD, dyslipidemia, previous stroke, and stroke etiology. ORc, as note b with additional adjustment for baseline SBP, DBP, FBG, and NIHSS; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; NIHSS: National Institutes of Health Stroke Scale